1. |
Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer, 2000, 36(4):476-482.
|
2. |
Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, 133(3421):571-573.
|
3. |
Sterling JA, Edwards JR, Martin TJ, et al. Advances in the biology of bone metastasis:how the skeleton affects tumor behavior. Bone, 2011, 48(1):6-15.
|
4. |
Sterling JA, Guelcher SA. Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep, 2011, 9(2):89-95.
|
5. |
Fidler IJ. The pathogenesis of cancer metastasis:the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 2003, 3(6):453-458.
|
6. |
Mundy GR. Metastasis to bone:causes, consequences and therape-utic opportunities. Nat Rev Cancer, 2002, 2(8):584-593.
|
7. |
Cawthorn TR, Amir E, Broom R, et al. Mechanisms and pathways of bone metastasis:challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis, 2009, 26(8):935-943.
|
8. |
Psaila B, Lyden D. The metastatic niche:adapting the foreign soil. Nat Rev Cancer, 2009, 9(4):285-293.
|
9. |
Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature, 1978, 276(5689):726-728.
|
10. |
Lee J, Weber M, Mejia S, et al. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer, 2001, 37(1):106-113.
|
11. |
Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-deriva-tive C4-2B prostate cancer cell line mineralizes in vitro. Prostate, 2001, 47(3):212-221.
|
12. |
Roodman GD. Mechanisms of bone metastasis. Discov Med, 2004, 4(22):144-148.
|
13. |
Moreau J, Anderson KM, Mauney JR, et al. Studies of osteotropism on both sides of the breast cancer-bone interaction. Ann N Y Acad Sci, 2007, 1117(11):328-344.
|
14. |
Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev, 2006, 25(4):621-633.
|
15. |
Rose AA, Siegel PM. Breast cancer-derived factors facilitate osteol-ytic bone metastasis. Bull Cancer, 2006, 93(9):931-943.
|
16. |
Kingsley LA, Fournier PG, Chirgwin JM, et al. Molecular biology of bone metastasis. Mol Cancer Ther, 2007, 6(10):2609-2617.
|
17. |
Buijs JT, Stayrook KR, Guise TA. TGF-β in the bone microenviron-ment:role in breast cancer metastases. Cancer Microenviron, 2011, 4(3):261-281.
|
18. |
Kozlow W, Guise TA. Breast cancer metastasis to bone:mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia, 2005, 10(2):169-180.
|
19. |
Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev, 2006, 25(4):541-549.
|
20. |
Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol, 2001, 19(15):3562-3571.
|
21. |
Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis:integrating tumor cell and stromal cell interactions. Bone, 2011, 48(1):54-65.
|
22. |
Ozbas S, Dafydd H, Purushotham AD. Bone marrow micrometas-tasis in breast cancer. Br J Surg, 2003, 90(3):290-301.
|
23. |
Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3(6):537-549.
|
24. |
Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist, 2003, 8(3):241-251.
|
25. |
王永胜, 吴炅, 于金明, 等译. 乳腺病学. 第4版. 济南:山东科学技术出版社, 2012:1527-1555.
|
26. |
Boxer DI, Todd CE, Coleman R, et al. Bone secondaries in breast cancer:the solitary metastasis. J Nucl Med, 1989, 30(8):1318-1320.
|
27. |
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010, 60(5):277-300.
|
28. |
Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer:a population-based analysis of U.S. Medicare benefi-ciaries, 1999-2006. Breast Cancer Res Treat, 2012, 131(1):231-238.
|
29. |
Trinkaus M, Simmons C, Myers J, et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer, 2010, 18(2):197-203.
|
30. |
Ono K, Galasko CS. Skeletal metastases. Clin Orthop Relat Res, 1995, 3(312):2-3.
|
31. |
Damron TA, Morgan H, Prakash D, et al. Critical evaluation of Mirels' rating system for impending pathologic fractures. Clin Orthop Relat Res, 2003, 415 Suppl:S201-S207.
|
32. |
Jensen AØ, Jacobsen JB, Nørgaard M, et al. Incidence of bone metas-tases and skeletal-related events in breast cancer patients:a popula-tion-based cohort study in Denmark. BMC Cancer, 2011, 11:29.
|
33. |
Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer, 2002, 2(11):862-871.
|
34. |
Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci, 2000, 5(1):75-81.
|
35. |
Bristow AR, Agrawal A, Evans AJ, et al. Can computerised tomogr-aphy replace bone scintigraphy in detecting bone metastases from breast cancer? A prospective study. Breast, 2008, 17(1):98-103.
|
36. |
Fontana A, Delmas PD. Markers of bone turnover in bone metas-tases. Cancer, 2000, 88(12 Suppl):2952-2960.
|
37. |
Koizumi M, Ogata E. Bone metabolic markers as gauges of metas-tasis to bone:a review. Ann Nucl Med, 2002, 16(3):161-168.
|
38. |
Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer, 2000, 82(4):858-864.
|
39. |
Coleman R, Brown J, Terpos E, et al. Bone markers and their prog-nostic value in metastatic bone disease:clinical evidence and future directions. Cancer Treat Rev, 2008, 34(7):629-639.
|
40. |
Mohammadzadeh M, Alikhah H, Zareh AG. Comparison of bone scan with carbohydrate antigen 15-3 for evaluation of bone metas-tasis of brest cancer. Pak J Biol Sci, 2010, 13(4):175-179.
|
41. |
Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of bisphosphonates. Cancer, 2000, 88(12 Suppl):2961-2978.
|
42. |
Selander K, Lehenkari P, Väänänen HK. The effects of bisphosphon-ates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int, 1994, 55(5):368-375.
|
43. |
Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts:tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone, 1995, 17(2):137-144.
|
44. |
Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases:long term follow-up of two randomized, placebo-controlled trials. Cancer, 2000, 88(5):1082-1090.
|
45. |
Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol, 1999, 17(3):846-854.
|
46. |
Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secon-dary to bone metastases. Cochrane Database Syst Rev, 2002, (2):CD002068.
|
47. |
Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev, 2005,(3):CD003474.
|
48. |
Schenk R, Eggli P, Fleisch H, et al. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int, 1986, 38(6):342-349.
|
49. |
Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates:an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci, 2007, 1117(11):209-257.
|
50. |
Machado M, Cruz LS, Tannus G, et al. Efficacy of clodronate, pami-dronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis:a meta-analysis of randomized clinical trials. Clin Ther, 2009, 31(5):962-979.
|
51. |
Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ, 2012, 15(1):175-184.
|
52. |
Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol, 2010, 37 Suppl 1:S53-S65.
|
53. |
Hamdy NA. Denosumab:RANKL inhibition in the management of bone loss. Drugs Today (Barc), 2008, 44(1):7-21.
|
54. |
Lewiecki EM, Miller PD, Mcclung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res, 2007, 22(12):1832-1841.
|
55. |
Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase Ⅱ study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 2007, 25(28):4431-4437.
|
56. |
Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer:subgroup analyses of a phase 3 study. Breast Cancer Res Treat, 2009, 118(1):81-87.
|
57. |
Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases:a systematic review. J Clin Oncol, 2007, 25(11):1423-1436.
|
58. |
Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractiona-tion radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys, 2003, 55(3):594-605.
|
59. |
Gerszten PC, Burton SA, Welch WC, et al. Single-fraction radiosur-gery for the treatment of spinal breast metastases. Cancer, 2005, 104 (10):2244-2254.
|
60. |
Ryu S, Jin R, Jin JY, et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manage, 2008, 35(3):292-298.
|